Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate

Strategies to Prevent and Treat Cardiovascular Risk in Cancer Patients

(2013) Daniela Cardinale et al.   SEMINARS IN ONCOLOGY

Epirubicin: Is it like doxorubicin in breast cancer? A clinical review

(2012) Mustafa Khasraw et al.   BREAST

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

(2010) Ilke Sipahi et al.   LANCET ONCOLOGY

Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: A randomized, double-blind, placebo-controlled study

(2009) Francesco Pelliccia et al.   ATHEROSCLEROSIS

Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats

(2009) Karol L. Thompson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

(2009) Stephen Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats

(2008) Philip Wenzel et al.   FREE RADICAL BIOLOGY AND MEDICINE

Persistence, Up to 18 Months of Follow-Up, of Epirubicin-Induced Myocardial Dysfunction Detected Early by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers

(2008) G. Mantovani et al.   ONCOLOGIST

Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells

(2007) Silvana Cianchetti et al.   ATHEROSCLEROSIS